<p>Frazier Life Sciences Management L.P. 在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第二季度增持了 Avidity Biosciences, Inc.（NASDAQ:RNA - 免费报告）19.0% 的股份。该基金在本季度额外购买了 100,000 股后，持有 625,000 股该生物技术公司的股票。Frazier Life Sciences Management L.P. 在最近一个季度末持有 Avidity Biosciences 0.49% 的股份，价值 17,750,000 美元。</p>
<ul>
<li>这只早期生物科技股票上涨了 400%——你现在应该买吗？</li>
</ul>
<p>其他几家大型投资者最近也调整了对该公司的持股。Wellington Management Group LLP 在第一季度将其在 Avidity Biosciences 的股份增加了 19.5%。Wellington Management Group LLP 现在持有 9,684,556 股该生物技术公司的股票，价值 285,888,000 美元，此前在上个季度购买了 1,578,459 股。挪威银行在第二季度购买了 Avidity Biosciences 的新股份，价值 28,261,000 美元。T. Rowe Price Investment Management Inc. 在第一季度获得了 Avidity Biosciences 的新股份，价值约 22,765,000 美元。Nuveen LLC 在第一季度购买了价值约 12,729,000 美元的 Avidity Biosciences 新股份。最后，Price T Rowe Associates Inc. MD 在第一季度将其在 Avidity Biosciences 的股份增加了 2.7%。Price T Rowe Associates Inc. MD 现在持有 11,338,098 股该生物技术公司的股票，价值 334,701,000 美元，此前在该期间购买了 295,275 股。</p>
<p>获取 <strong>Avidity Biosciences</strong> 的提醒：</p>
<h2>Avidity Biosciences 的内部买卖</h2>
<p>在相关消息中，内部人士 Steven George Hughes 于 10 月 22 日星期三出售了 2,209 股 Avidity Biosciences 的股票。股票以平均价格 47.54 美元出售，总价值为 105,015.86 美元。交易完成后，该内部人士持有 38,867 股公司股票，价值约 1,847,737.18 美元。此交易代表其持股减少了 5.38%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。此外，内部人士 Teresa Mccarthy 于 10 月 15 日星期三出售了 20,000 股公司的股票。股票以平均价格 50.15 美元出售，总交易额为 1,003,000.00 美元。交易后，该内部人士持有 97,130 股公司股票，价值 4,871,069.50 美元。此交易代表其持股减少了 17.08%。该销售的 SEC 文件提供了更多信息。在上个季度，内部人士共出售了 30,979 股公司股票，价值 1,495,400 美元。公司内部人士持有公司股票的 3.83%。</p>
<h2>分析师评级变动</h2>
<p>RNA 最近成为多份分析师报告的主题。华尔街 Zen 在 10 月 25 日的研究报告中将 Avidity Biosciences 的评级从 “卖出” 上调至 “持有”。Loop Capital 在 10 月 28 日的报告中对 Avidity Biosciences 的股票设定了 72.00 美元的目标价。Chardan Capital 在 11 月 11 日的研究报告中重申了 “中性” 评级，并对 Avidity Biosciences 的股票设定了 72.00 美元的目标价。美国银行在 9 月 15 日的研究报告中将 Avidity Biosciences 的目标价从 56.00 美元上调至 65.00 美元，并给予该股票 “买入” 评级。最后，花旗集团在 10 月 27 日的研究报告中将 Avidity Biosciences 的股票评级从 “买入” 下调至 “持有”。九位研究分析师对该股票给予 “买入” 评级，十三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，共识目标价为 69.24 美元。</p>
<p><strong>查看我们最新的 RNA 股票报告</strong></p>
<h2>Avidity Biosciences 股票上涨 0.3%</h2>
<p>NASDAQ RNA 的股票在周五开盘时为 71.83 美元。该公司的市值为 108.2 亿美元，市盈率为-17.18，贝塔值为 0.90。该公司的 50 日移动平均价格为 64.10 美元，200 日移动平均价格为 47.12 美元。Avidity Biosciences, Inc.的 1 年最低价为 21.51 美元，1 年最高价为 71.88 美元。</p>
<p>Avidity Biosciences（NASDAQ:RNA - 获取免费报告）最近在 11 月 10 日星期一发布了其财报。该生物技术公司报告本季度每股收益（EPS）为（1.27 美元），低于市场共识预期的（1.05 美元）0.22 美元。Avidity Biosciences 的净利润率为-2,634.59%，股本回报率为-37.70%。该公司在本季度的收入为 1248 万美元，而分析师预期为 180 万美元。该公司的收入同比增长 420.8%。股票研究分析师预测 Avidity Biosciences, Inc.在本年度将发布-2.89 的每股收益。</p>
<h2>Avidity Biosciences 公司简介</h2>
<p>（免费报告）</p>
<p>Avidity Biosciences, Inc.是一家生物制药公司，专注于 RNA 治疗的递送。它开发的抗体寡核苷酸结合物（AOC）旨在治疗以前无法用 RNA 治疗的疾病。该公司的主要产品候选 AOC 1001 用于治疗肌强直性营养不良症 1 型，这是一种罕见的单基因肌肉疾病，目前处于 1/2 期临床试验中。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Avidity Biosciences</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>Synopsys 因 Ansys 整合推动增长而看涨</li>
<li>股票评级和建议：理解分析师评级</li>
<li>你能给自己最好的节日礼物是什么？Costco 股票</li>
<li>关注国会股票交易</li>
<li>为什么 Zscaler 股票在经历 30% 的抛售后可能准备反弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk5B?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk5B"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Avidity Biosciences 吗？</h2>
<p>在考虑 Avidity Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Avidity Biosciences 并不在名单上。</p>
<p>虽然 Avidity Biosciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Frazier Life Sciences Management L.P. 在第二季度将其在 Avidity Biosciences 的股份增加了 19%，目前持有 625,000 股，价值 1,775 万美元。其他投资者如 Wellington Management 和 Norges Bank 也调整了他们的持股。公司内部人士进行了显著的股票出售。分析师对 Avidity Biosciences 的评级意见不一，普遍维持 “持有” 评级，目标价为 69.24 美元。该股票目前交易价格为 71.83 美元，市值为 108.2 亿美元</p>

<p>Frazier Life Sciences Management L.P. boosted its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 19.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 625,000 shares of the biotechnology company's stock after acquiring an additional 100,000 shares during the quarter. Frazier Life Sciences Management L.P. owned 0.49% of Avidity Biosciences worth $17,750,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Frazier Life Sciences Management L.P. 在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第二季度增持了 Avidity Biosciences, Inc.（NASDAQ:RNA - 免费报告）19.0% 的股份。该基金在本季度额外购买了 100,000 股后，持有 625,000 股该生物技术公司的股票。Frazier Life Sciences Management L.P. 在最近一个季度末持有 Avidity Biosciences 0.49% 的股份，价值 17,750,000 美元。</p>
</div><ul>
<li>This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>这只早期生物科技股票上涨了 400%——你现在应该买吗？</li>
</ul>
</div><p>Several other large investors have also recently modified their holdings of the business. Wellington Management Group LLP grew its stake in shares of Avidity Biosciences by 19.5% in the first quarter. Wellington Management Group LLP now owns 9,684,556 shares of the biotechnology company's stock worth $285,888,000 after purchasing an additional 1,578,459 shares during the last quarter. Norges Bank bought a new position in Avidity Biosciences during the 2nd quarter worth $28,261,000. T. Rowe Price Investment Management Inc. acquired a new position in Avidity Biosciences during the 1st quarter worth about $22,765,000. Nuveen LLC bought a new stake in shares of Avidity Biosciences in the 1st quarter valued at about $12,729,000. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Avidity Biosciences by 2.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 11,338,098 shares of the biotechnology company's stock valued at $334,701,000 after buying an additional 295,275 shares during the period.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也调整了对该公司的持股。Wellington Management Group LLP 在第一季度将其在 Avidity Biosciences 的股份增加了 19.5%。Wellington Management Group LLP 现在持有 9,684,556 股该生物技术公司的股票，价值 285,888,000 美元，此前在上个季度购买了 1,578,459 股。挪威银行在第二季度购买了 Avidity Biosciences 的新股份，价值 28,261,000 美元。T. Rowe Price Investment Management Inc. 在第一季度获得了 Avidity Biosciences 的新股份，价值约 22,765,000 美元。Nuveen LLC 在第一季度购买了价值约 12,729,000 美元的 Avidity Biosciences 新股份。最后，Price T Rowe Associates Inc. MD 在第一季度将其在 Avidity Biosciences 的股份增加了 2.7%。Price T Rowe Associates Inc. MD 现在持有 11,338,098 股该生物技术公司的股票，价值 334,701,000 美元，此前在该期间购买了 295,275 股。</p>
</div><p>Get <strong>Avidity Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Avidity Biosciences</strong> 的提醒：</p>
</div><h2>Insider Buying and Selling at Avidity Biosciences</h2>
<div class="lb-trans"><h2>Avidity Biosciences 的内部买卖</h2>
</div><p>In related news, insider Steven George Hughes sold 2,209 shares of Avidity Biosciences stock in a transaction on Wednesday, October 22nd. The shares were sold at an average price of $47.54, for a total value of $105,015.86. Following the completion of the sale, the insider owned 38,867 shares of the company's stock, valued at approximately $1,847,737.18. This trade represents a 5.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Teresa Mccarthy sold 20,000 shares of the business's stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $50.15, for a total transaction of $1,003,000.00. Following the sale, the insider owned 97,130 shares of the company's stock, valued at $4,871,069.50. This trade represents a 17.08% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 30,979 shares of company stock valued at $1,495,400. Company insiders own 3.83% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Steven George Hughes 于 10 月 22 日星期三出售了 2,209 股 Avidity Biosciences 的股票。股票以平均价格 47.54 美元出售，总价值为 105,015.86 美元。交易完成后，该内部人士持有 38,867 股公司股票，价值约 1,847,737.18 美元。此交易代表其持股减少了 5.38%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。此外，内部人士 Teresa Mccarthy 于 10 月 15 日星期三出售了 20,000 股公司的股票。股票以平均价格 50.15 美元出售，总交易额为 1,003,000.00 美元。交易后，该内部人士持有 97,130 股公司股票，价值 4,871,069.50 美元。此交易代表其持股减少了 17.08%。该销售的 SEC 文件提供了更多信息。在上个季度，内部人士共出售了 30,979 股公司股票，价值 1,495,400 美元。公司内部人士持有公司股票的 3.83%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>RNA has been the topic of a number of recent analyst reports. Wall Street Zen raised Avidity Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, October 25th. Loop Capital set a $72.00 price target on shares of Avidity Biosciences in a report on Tuesday, October 28th. Chardan Capital restated a &#34;neutral&#34; rating and issued a $72.00 price target on shares of Avidity Biosciences in a research report on Tuesday, November 11th. Bank of America increased their price objective on shares of Avidity Biosciences from $56.00 to $65.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday, September 15th. Finally, Citigroup downgraded shares of Avidity Biosciences from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, October 27th. Nine research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of &#34;Hold&#34; and a consensus price target of $69.24.</p>
<div class="lb-trans"><p>RNA 最近成为多份分析师报告的主题。华尔街 Zen 在 10 月 25 日的研究报告中将 Avidity Biosciences 的评级从 “卖出” 上调至 “持有”。Loop Capital 在 10 月 28 日的报告中对 Avidity Biosciences 的股票设定了 72.00 美元的目标价。Chardan Capital 在 11 月 11 日的研究报告中重申了 “中性” 评级，并对 Avidity Biosciences 的股票设定了 72.00 美元的目标价。美国银行在 9 月 15 日的研究报告中将 Avidity Biosciences 的目标价从 56.00 美元上调至 65.00 美元，并给予该股票 “买入” 评级。最后，花旗集团在 10 月 27 日的研究报告中将 Avidity Biosciences 的股票评级从 “买入” 下调至 “持有”。九位研究分析师对该股票给予 “买入” 评级，十三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，共识目标价为 69.24 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on RNA</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 RNA 股票报告</strong></p>
</div><h2>Avidity Biosciences Trading Up 0.3%</h2>
<div class="lb-trans"><h2>Avidity Biosciences 股票上涨 0.3%</h2>
</div><p>Shares of NASDAQ RNA opened at $71.83 on Friday. The firm has a market capitalization of $10.82 billion, a P/E ratio of -17.18 and a beta of 0.90. The firm's 50-day moving average price is $64.10 and its 200-day moving average price is $47.12. Avidity Biosciences, Inc. has a 1-year low of $21.51 and a 1-year high of $71.88.</p>
<div class="lb-trans"><p>NASDAQ RNA 的股票在周五开盘时为 71.83 美元。该公司的市值为 108.2 亿美元，市盈率为-17.18，贝塔值为 0.90。该公司的 50 日移动平均价格为 64.10 美元，200 日移动平均价格为 47.12 美元。Avidity Biosciences, Inc.的 1 年最低价为 21.51 美元，1 年最高价为 71.88 美元。</p>
</div><p>Avidity Biosciences (NASDAQ:RNA - Get Free Report) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.22). Avidity Biosciences had a negative net margin of 2,634.59% and a negative return on equity of 37.70%. The firm had revenue of $12.48 million during the quarter, compared to analyst estimates of $1.80 million. The business's revenue was up 420.8% on a year-over-year basis. Equities research analysts forecast that Avidity Biosciences, Inc. will post -2.89 EPS for the current year.</p>
<div class="lb-trans"><p>Avidity Biosciences（NASDAQ:RNA - 获取免费报告）最近在 11 月 10 日星期一发布了其财报。该生物技术公司报告本季度每股收益（EPS）为（1.27 美元），低于市场共识预期的（1.05 美元）0.22 美元。Avidity Biosciences 的净利润率为-2,634.59%，股本回报率为-37.70%。该公司在本季度的收入为 1248 万美元，而分析师预期为 180 万美元。该公司的收入同比增长 420.8%。股票研究分析师预测 Avidity Biosciences, Inc.在本年度将发布-2.89 的每股收益。</p>
</div><h2>Avidity Biosciences Profile</h2>
<div class="lb-trans"><h2>Avidity Biosciences 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.</p>
<div class="lb-trans"><p>Avidity Biosciences, Inc.是一家生物制药公司，专注于 RNA 治疗的递送。它开发的抗体寡核苷酸结合物（AOC）旨在治疗以前无法用 RNA 治疗的疾病。该公司的主要产品候选 AOC 1001 用于治疗肌强直性营养不良症 1 型，这是一种罕见的单基因肌肉疾病，目前处于 1/2 期临床试验中。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Avidity Biosciences</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>Synopsys Sees Bullish Shift as Ansys Integration Drives Growth</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>The Best Holiday Present You Can Give Yourself? Costco Stock</li>
<li>Following Congress Stock Trades</li>
<li>Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Avidity Biosciences</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>Synopsys 因 Ansys 整合推动增长而看涨</li>
<li>股票评级和建议：理解分析师评级</li>
<li>你能给自己最好的节日礼物是什么？Costco 股票</li>
<li>关注国会股票交易</li>
<li>为什么 Zscaler 股票在经历 30% 的抛售后可能准备反弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk5B" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=RNA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Avidity Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Avidity Biosciences 吗？</h2>
</div><p>Before you consider Avidity Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Avidity Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avidity Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Avidity Biosciences 并不在名单上。</p>
</div><p>While Avidity Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Avidity Biosciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Frazier 生命科学管理公司在 Avidity Biosciences 公司持有价值 1775 万美元的股票